Increased pulmonary embolism and mortality risk with 10mg Xeljanz - The Pharma Letter

Increased pulmonary embolism and mortality risk with 10mg Xeljanz  The Pharma Letter

Pfizer has been forced to move patients off the 10mg twice daily dose of its rheumatoid arthritis (RA) drug Xeljanz (tofacitinib) in a post-marketing requiremen.